Diagnosticos da America (BSP:DASA3) ROCE %: 9.29% (As of Mar. 2026)


BSP:DASA3 Diagnosticos da America SA BSP:DASA3
46 GF Score
Price R$2.78
GF Value R$1.70
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Diagnosticos da America ROCE %?

Diagnosticos da America BSP:DASA3 -1.42% 46 ROCE % is 9.29% as of Mar. 2026. GuruFocus rates BSP:DASA3 with a GF Score™ of 46/100 and a GF Value™ of R$1.70 (Significantly Overvalued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Diagnosticos da America's annualized ROCE % for the quarter that ended in Mar. 2026 was 9.29%.

Diagnosticos da America  (BSP:DASA3) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Diagnosticos da America ROCE % Related Terms

Diagnosticos da America ROCE % Historical Data

* Premium members only.

The historical data trend for Diagnosticos da America's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diagnosticos da America ROCE % Chart

Diagnosticos da America Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.12 5.94 3.86 2.98 5.21

Diagnosticos da America Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.57 10.23 10.74 -10.08 9.29
BSP:DASA3
46GF Score
Diagnosticos da America SA BSP:DASA3
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diagnosticos da America ROCE % Calculation

Diagnosticos da America's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=915.237/( ( (26458.471 - 5299.051) + (18562.235 - 4563.222) )/ 2 )
=915.237/( (21159.42+13999.013)/ 2 )
=915.237/17579.2165
=5.21 %

Diagnosticos da America's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=1298.696/( ( (18562.235 - 4563.222) + (17814.511 - 3853.593) )/ 2 )
=1298.696/( ( 13999.013 + 13960.918 )/ 2 )
=1298.696/13979.9655
=9.29 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 9.29% mean?
Diagnosticos da America (BSP:DASA3) has a ROCE % of 9.29% as of Mar. 2026.
Is Diagnosticos da America's ROCE % too high?
Diagnosticos da America's current ROCE % is 9.29%. Overall, Diagnosticos da America has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Diagnosticos da America's ROCE % compare to TMO and DHR?
Diagnosticos da America's ROCE % of 9.29% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Diagnostics & Research company?
A good ROCE % depends on the Medical Diagnostics & Research industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Diagnosticos da America's current ROCE % is 9.29%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diagnosticos da America stock overvalued right now?
Based on GuruFocus' analysis, Diagnosticos da America (BSP:DASA3) is currently considered Significantly Overvalued. The stock's GF Value™ is R$1.70, compared to a current price of R$2.78 — trading 63.5% above its estimated fair value. The current ROCE % is 9.29%. Diagnosticos da America's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Diagnosticos da America (BSP:DASA3), the current ROCE % is 9.29% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diagnosticos da America (BSP:DASA3) Overvalued in 2026?

Based on GuruFocus' analysis, Diagnosticos da America stock appears to be overvalued. The current stock price of R$2.78 is trading 63.5% above its estimated GF Value™ of R$1.70. GuruFocus considers Diagnosticos da America to be Significantly Overvalued.

Key valuation signals for BSP:DASA3:

  • ROCE %: 9.29%
  • GF Value™: R$1.70 vs. price of R$2.78 (63.5% above fair value)
  • GF Score™: 46/100 with 3 warning signs

No single metric tells the full story. See the BSP:DASA3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diagnosticos da America Business Description

Address Avenida Jurua, 434, Alphaville, Barueri, SP, BRA, 06455-010
Diagnosticos da America SA operates as a medical diagnostics company in Brazil. The company offers clinical analysis, diagnostic imaging tests, and patient service centers. It has three operating segments. Outpatient care services and care coordination includes Diagnosis and health management, Hospitals and oncology include Medical and hospital services & Foreign operations include Diagnosis. The majority is from the Hospitals and oncology segment. Geographically, it operates in Brazil and South America (Argentina, Uruguay, Chile and Colombia).
46GF Score

Get the complete analysis for BSP:DASA3

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$2.78
Price
R$1.70
GF Value